C4 Therapeutics, Inc. (CCCC)
NASDAQ:CCCC
Want to see CCCC full AI Analyst Report?
CCCC Stock Chart & Stats
$2.92
-$0.05(-1.30%)
At close: 4:00 PM EST
$2.92
-$0.05(-1.30%)
Day’s Range― - ―
52-Week Range$1.36 - $4.60
Previous CloseN/A
Volume165.25K
Average Volume (3M)2.77M
Market Cap
$471.02M
Enterprise Value$321.86M
Total Cash (Recent Filing)$235.67M
Total Debt (Recent Filing)$58.45M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Aug 12, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding110,567,220
10 Day Avg. Volume2,168,734
30 Day Avg. Volume2,765,733
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue9.23
Enterprise Value/Gross Profit9.74
Enterprise Value/Ebitda-3.21
Forecast
1Y Price Target
$10.33Price Target Upside253.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$22.84M
Bulls Say, Bears Say
Bulls Say
Strategic Roche CollaborationThe broadened Roche deal provides meaningful non-dilutive funding, tiered royalties and leverages Roche for development, regulatory and commercialization. This durable partnership reduces execution risk, validates TORPEDO platform and enhances long-term commercial optionality for DAC modalities.
Solid Cash RunwayA reported cash balance and runway through end-2028 materially lowers near-term refinancing risk and supports multiple clinical programs through key readouts. This runway gives management time to hit milestones, de-risk assets and secure value-driving partnerships without immediate dilution.
Clinical Proof-of-Concept ProgressRobust Phase 1 cemsidomide data in heavily pretreated multiple myeloma (53% ORR at RP2D, deepening responses, MRD negativity in some) indicates clinical proof-of-concept. Durable efficacy and tolerability strengthen registrational prospects, partner interest and long-term pipeline value for hematologic oncology.
Bears Say
High Cash BurnSustained negative operating and free cash flow near -$95M TTM implies ongoing heavy cash consumption to fund R&D. Over a multi-quarter horizon this elevates dilution or milestone-dependency risk if partnerships or milestone receipts are delayed, pressuring capital structure and strategic flexibility.
Deep Profitability LossesExtremely negative margins and returns reflect that operating expenses far exceed current revenues. This structural loss profile means the business must materially grow revenue or obtain recurrent partner funding to reach breakeven, highlighting long-term profitability uncertainty and potential equity erosion.
Modest, Declining Revenue BaseLow and falling revenue increases reliance on milestone and collaboration payments rather than recurring product sales. Without clear, sustainable revenue growth, the company faces persistent operating deficits and limited capacity to internally fund expanded development or commercialization investments.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics, Inc.’s price range in the past 12 months?
C4 Therapeutics, Inc. lowest stock price was $1.36 and its highest was $4.60 in the past 12 months.
What is C4 Therapeutics, Inc.’s market cap?
C4 Therapeutics, Inc.’s market cap is $471.02M.
When is C4 Therapeutics, Inc.’s upcoming earnings report date?
C4 Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 44 days.
How were C4 Therapeutics, Inc.’s earnings last quarter?
C4 Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.251 by $0.051.
Is C4 Therapeutics, Inc. overvalued?
According to Wall Street analysts C4 Therapeutics, Inc.’s price is currently Undervalued.
Does C4 Therapeutics, Inc. pay dividends?
C4 Therapeutics, Inc. does not currently pay dividends.
What is C4 Therapeutics, Inc.’s EPS estimate?
C4 Therapeutics, Inc.’s EPS estimate is -0.21.
How many shares outstanding does C4 Therapeutics, Inc. have?
C4 Therapeutics, Inc. has 110,567,220 shares outstanding.
What happened to C4 Therapeutics, Inc.’s price movement after its last earnings report?
C4 Therapeutics, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.251. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of C4 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CCCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C4 Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (253.88% Upside)
$10.33 (253.88% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 306.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
180.26%
12-Months-Change
Fundamentals
Return on Equity
-50.68%
Trailing 12-Months
Asset Growth
2.92%
Trailing 12-Months
Company Description
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$10.33
▲(253.88% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
2.96% Insiders
8.63% Mutual Funds
34.52% Other Institutional Investors
47.50% Public Companies and
Individual Investors